Best Life Sciences Platforms and Tools Companies in Ohio, United States

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Because of its stability, small size and molecular makeup, it maintains its function in vivo without triggering the body's immune system. Further, it can function without toxic side effects common in treatments involving larger and less stable compounds. Due to the results achieved over the last three years of testing in areas such as Stem Cells, Inflammation, Oxidation Stress and Diabetes treatment, the company is now preparing a submission to enter into phase I and II in human clinical trials.

Biotech imaging solutions: CryoViz & IschemiaViz for preclinical and clinical applications. They specialize in advanced imaging technologies and software for biotechnology problems. Their core competency lies in CryoViz imaging, offering high-resolution, large field-of-view microscopic imaging with 3D reconstruction and specialized image processing. This technology bridges the gap between in vivo imaging and histology, enabling detailed analysis from whole organisms to sub-cellular levels. Applications span stem cells, cancer research, molecular imaging, gene expression, toxicology, biomarker validation, and anatomical phenotyping. They also offer IschemiaViz, an AI-powered software for cardiac perfusion CT analysis, aiding cardiologists in diagnosing cardiovascular disease. They provide imaging services, analyzing samples and delivering results with sensitivity and precision. Their solutions cater to both preclinical and clinical markets, offering tools for cellular and molecular imaging, multi-spectral fluorescence, and automated 3D visualization.

{}

Funding rounds

• Mar 2025Grant (prize money)$1.2M
• Sep 2020Grant (prize money)$1M
• Jul 2019Seed$220K
• Feb 2019Grant (prize money)$250K

Founders & team

Bo WangCo-FounderPrabir DuttaCo-FounderSteve JonesCo-Founder & CEO

Investors

Ohio.gov, America’s Seed Fund, National Science Foundation, Rev1 Ventures, MassChallenge

Sus Clinicals provides testing services for preclinical solutions using pig models. It performs cancer-related genetic tests using pig models. The company produces its proprietary genetically-modified pig models for preclinical testing. It is used in the identification of drugs, toxicity testing, and diagnostic purpose.

Funding rounds

• Sep 2023Grant (prize money)$2M
• Aug 2023Series A$3.7M

Founders & team

Jeff WeedmanCEO

Investors

HHS

Stirling Ultracold manufactures freezers for the scientific, electronics, and medical communities. It uses a free-piston Stirling engine. Products include COMPACT SU105U, UPRIGHT SU780XLE, PORTABLE ULT25NEU, and more.

Molecular imaging tech revolutionizing cancer surgery with high-resolution probes. They are dedicated to developing fluorescent molecular probe technologies that enhance cancer surgery and diagnostics. Their FIRE technology provides surgeons with precise visualization of tumors, especially at tumor margins, enabling complete resection. The company's quenched, activity-based probes ensure signal only appears when cancer is detected, minimizing background fluorescence. This innovative approach aims to improve patient outcomes, reduce complications, and enhance survival rates. They focus on clinical translation, offering flexible and high-performance probes designed for real-world surgical needs. Their technology supports various application methods, including in vivo and ex vivo, with the goal of positively impacting healthcare economics.

Funding rounds

• Sep 2022Grant (prize money)$1.8M
• Sep 2019Grant (prize money)$281.7K
• Aug 2014Grant (prize money)$149.8K

Founders & team

Brian StraightPresident and CEO

Investors

HHS, AIM-HI Accelerator Fund, BioEnterprise

Provider of molecular diagnostic solutions to stroke. The company uses its proprietary ISCDx test which is used to analyze the RNA expression of blood biomarkers to identify the cause of stroke. The company's program Biomarkers of Acute Stroke Etiology (BASE) study (NCT02014896) is an observational study that uses RNA gene expression in to identify the aetiology of acute ischemic stroke.

Diagnostic Hybrids develops and manufactures cellular and molecular diagnostic kits for various applications in detecting a range of respiratory diseases, herpes infections, thyroid function, and other markers of diseases. The company offers a D3 FastPoint L-DFA influenza A/influenza B virus identification kit, which allows for the identification of influenza A virus and influenza B virus from a patient’s specimen in under 30 minutes. It also develops and commercializes genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry with a focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines.

Provider of biomimetic materials to support and regenerate bone. Its technology encompasses novel synthetic calcium phosphate-based cement that is suitable for several clinical applications, including bone voids, treatment of various fractures and spinal disorders. The product is available in various forms, such as injectable and moldable putty, granules, and structural blocks for orthopedic and spine surgery.

Funding rounds

• Sep 2020Seed$1.1M
• Apr 2017Seed$2.5M

Founders & team

Sarit Bhaduri Dfacers Faimbe FnaiCo-Founder and Board Member

SapVax is developing self-adjuvanting peptide vaccine immunotherapies for cancer. It is a spin-off from the University of Auckland in New Zealand. The biotech has a proprietary chemistry platform for coupling immunogenic peptides to TLR2-agonist adjuvants (synthetic long peptide antigens and palmitate-derived lipopeptide TLR2 agonists) to generate fully-synthetic, self-adjuvanting cancer vaccines. It has an initial focus on NY-ESO-1-positive tumors. The company hopes that their therapies will work as co-treatment with checkpoint inhibitors. The company is based out of the accelerator, BioMotiv.

Funding rounds

• Jan 2019Series A$3.2M

Founders & team

Baiju ShahCEO

Investors

BioEnterprise

Developer of botanical extraction equipment intended to offer tailored services for end-to-end botanical extraction. The company's equipment uses a series of technologies that coalesce into an easy-to-use benchtop device that can streamline the extraction process, enabling businesses to optimize their entire resource chain to the one goal of profit maximization.

Founders & team

Matthew AndersonCo-Founder & CEO

Investors

Entourage Effect Capital

Tech stack

Wix EcommerceWixReactGoogle CloudGoogle AdsPolyfill

3D nanofiber scaffolds for regenerative medicine, veterinary, and cell culture. They design and manufacture innovative three-dimensional nanofiber scaffolds that mimic the extracellular matrix, creating a realistic environment for cells. Their platform technology supports regenerative medicine, veterinary applications, and 3D cell culture. They build complex structures for revolutionary products in these markets. They offer scaffolds for organ and tissue regeneration, along with products like nanofiber plates, chamber slides, and custom scaffolds. Their products enhance cancer research, stem cell growth, disease modeling, and drug discovery. They provide a natural tissue technology platform, offering surgeons soft tissue solutions. They manufacture enhanced cell culture plates to support basic research and drug discovery in academic and pharmaceutical labs.